#SaudiPharma #Semaglutide #PeptideAPI #SaudiArabia #KSA #PharmaSourcing #API #CDMO #PharmaSupplyChain

Stay ahead of what’s shaping biopharma outsourcing. Get free industry news, expert perspectives, and practical insights from Outsourced Pharma.
Sign up for free: www.outsourcedpharma.com/user/new
Surviving the thaw is only the first step.
Viability alone doesn’t show how consistently cells attach, regain morphology and return to productive growth. CytoBoost™ REVIVE supports stronger post-thaw recovery.
Talk to Adam: [email protected]
Made Scientific Buys Pennsylvania Cell-Therapy Plant Made Scientific acquired an operating 85,000-square-foot cell-therapy manufacturing facility...
https://www.narrowit.com/news/made-scientific-pennsylvania-cell-therapy-facility-2026-09-21
#MadeScientific #NationalResilience #CellTherapy #CDMO
Looking beyond short-term turmoil, Syngene has revamped its leadership and is building capacity as it eyes growth and emerging modalities
CordenPharma Expands Aseptic Filling Capacity to 500 Million Injectable Units Annually #Italy #CDMO #CordenPharma #sterile_injectables #Caponago
CordenPharma Expands Aseptic Filling Capacity to 500 Million Sterile Injectable Units Annually #Switzerland #CDMO #CordenPharma #Caponago #EUA
CordenPharma Expands Aseptic Filling Capacity to 500 Million Sterile Injectable Units Annually #Switzerland #CDMO #CordenPharma #sterile_injectables #Caponago
Scinai Immunotherapeutics (NASDAQ: SCNI) refocuses R&D on its NanoAb platform with two IL-17 programs and targets ~$5M in CDMO revenue for 2026 after terminating PC111 licensing arrangements. #Biotech #CDMO
Pharmaceutical CDMO Market Expected to Grow to US$ 270.3 Billion by 2031 Driven by Biologic Demand #None #pharmaceutical #CDMO #Biologics
Scinai Immunotherapeutics Shifts Focus to NanoAb and CDMO Growth Strategies #Scinai_Immunotherapeutics #Israel #Jerusalem #CDMO #NanoAb_Platform